Jeff Marrazzo co-founded Spark Therapeutics in 2013 and has led the growth of the company from a research center within the Children’s Hospital of Philadelphia to a fully integrated, commercial gene therapy company.

Under Jeff’s leadership, Spark received regulatory approval for the first gene therapy for a genetic disease in both the U.S. and EU, launched the first gene therapy for a genetic disease in the U.S., and established human proof-of-concept of Spark’s gene therapy platform in both the retina and liver. In more than eight years, Jeff has built an organization of more than 700 employees while securing over $1 billion in capital and successfully orchestrating a merger with Roche.

Outside of his role with Spark, Jeff currently serves on the boards of the Life Science Cares Philadelphia and The Rendell Center for Civics and Civic Engagement. Jeff received a B.A. in economics and B.S.E. in systems science and engineering from the University of Pennsylvania. He also holds a dual M.B.A. / M.P.A. from The Wharton School of the University of Pennsylvania and Harvard Kennedy School, a program which he founded.